

CIN: L27100TG1989PLC010122
ZENOTECH LABORATORIES LIMITED

Registered Office & Factory:

Survey No.250 -252 Turkapally Village Shamirpet Mandal Hyderabad - 500 078 T.S., India.

Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com

Date: January 27, 2023

The Manager **BSE Limited (DCS- CRD)**Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai – 400 001

Scrip Code: 532039

Dear Sir,

<u>Sub: Outcome of the Board Meeting of Zenotech Laboratories Limited (the Company) held today - Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2022</u>

With reference to the intimation of Board Meeting submitted on January 19, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 27, 2023 which commenced at 5:30 p.m. IST and ended at 7:15 p.m. IST.

The Board has, *inter-alia*, approved Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2022.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report thereon issued by the Statutory Auditors of the Company.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For Zenotech Laboratories Limited

Abdul Gafoor Mohammad Company Secretary & Compliance Officer ICSI Membership No. A22331

Encl: as above

ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078 Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com Extract of Standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December 2022

(Rs in lakhs, except share and per equity share data)							
Sl.		Quarter ended Nine months ended					Year ended
No.	Particulars	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
110.		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	777.73	927.18	925.94	2,839.69	2,509.40	3,249.37
II	Other Operating Income	101.80	101.82	101.80	305.39	305.39	407.14
III	Other Income	16.34	64.67	3.62	85.85	13.73	62.93
IV	Total Income (I+II+III)	895.87	1,093.67	1,031.36	3,230.93	2,828.52	3,719.44
	_						
V	Expenses			0.01	6.00	0.05	0.11
	a). Cost of materials consumed	-	-	0.01	6.08	0.05	0.11
	b). Purchase of Stock-in-Trade	-	-	-	-	-	-
	c). Changes in inventories of finished goods, work-in-	-	-	-	-	-	-
	progress and stock-in-trade	400.00					
	d). Employee benefit expenses	199.02	192.17	175.10	582.86	523.71	709.52
	e). Finance costs	-	-	26.98	11.22	106.73	121.52
	f). Depreciation and amortization expense	180.46	180.53	171.75	539.59	524.55	697.35
	g). Other Expenses	323.33	336.03	296.25	989.28	867.92	1,200.81
X 77	Total expenses	702.81	708.73	670.09	2,129.03	2,022.96	2,729.31
VI	Profit/(Loss) before exceptional items and tax (IV-V)	193.06	384.94	361.27	1,101.90	805.56	990.13
VII	Exceptional items	ı	-	ı	ı	1	-
	Profit/(Loss) before tax (VI-VII)	193.06	384.94	361.27	1,101.90	805.56	990.13
IX	Tax expense						
	a). Current Tax	-	-	-	-	-	-
	b). Deferred Tax	54.89	108.44	-	310.17	-	(1,227.46)
	Total Tax Expense (IX)	54.89	108.44	-	310.17	-	(1,227.46)
X	Profit/(Loss) for the period (VIII-IX)	138.17	276.50	361.27	791.73	805.56	2,217.59
XI	Other Comprehensive Income						
	a). Items that will not be reclassified to Profit or Loss						
	Re - measurement of the defined benefit obligations	1.40	1.40	(0.14)	4.20	(0.43)	5.60
	b). Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	Less: Income Tax	(0.35)	(0.35)	-	(1.06)	-	-
XII	Total Comprehensive Income for the period (X+/-XI)	139.22	277.55	361.41	794.87	805.99	2,223.19
XIII	Paid-up equity share capital (Face value of₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e.Other equity						960.95
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)						
	a). Basic	0.23	0.45	0.59	1.30	1.32	3.63
	a) Diluted	0.23	0.45	0.59	1.30	1.32	3.63
See accompanying notes to the financial results							

Notes:

- 1. The above financial results for the quarter ended December 31, 2022 have been reviewed by the Audit Committee meeting held on 27th January, 2023 and approved by the Board of Directors of the Company at their meeting held on the same day and have undergone a 'limited review' by the Statutory Auditors of the Company.
- 2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
- 4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June, 2022 and Long Form Standing certificate dated 15th June, 2022 respectively, received from concerned authorities. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence no longer CFS is applicable.
- 5. The financial results have been prepared on a going concern basis, considering that the Company is well placed to meet the cash burn requirements in the coming periods.
- 6. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
- 7. The Company has only one segment, i.e. Pharmaceuticals.
- 8. Figures for previous period/year have been regrouped to conform to the current period presentation.

By Order of the Board

Chairman DIN: 01219312

Place: New Delhi Date: 27-January-2023

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company

Review report to the Board of Directors of Zenotech Laboratories Limited

 We have reviewed the unaudited financial results ("the Statement") of Zenotech Laboratories Limited ("the Company") for the quarter and nine month ended 31st December 2022, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), which has been initialed by us for identification.

2. Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. Auditor's Responsibility

Our responsibility is to express a conclusion on this Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company

SAPPERSONNEL and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly,

Office Unit no: 609, Jain Sadguru Images Capital Park,6th Floor, Plot No: -1-98/4/1-12 28 & 29, Image Garden Road, Madhapur village, Serilingampally, Hyderabad-500081, Telangana Ph:040 29323743/29332743

Head Office/Registered Office • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004,India Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB-6552(Registration No. with ICAI is 003990S/S200018.

4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FIRM REGN. NO.

For PKF Sridhar & Santhan

Chartered Accountants

Firm Registration No. 003990

Viswanadh VNSS Kuchi

Partner

Membership No. 210789

Place: Hyderabad

Date: 27-01-2023 UDIN: 23210789BGYTAM3713